|
Baseline variable
|
12-month HAQ-DI score
|
12-month change in HAQ-DI score
|
12-month EQ-5D-3L score
|
12-month change in EQ-5D-3L score
|
|---|
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
|---|
|
β
|
P
|
β
|
P
|
β
|
P
|
β
|
P
|
β
|
P
|
β
|
P
|
β
|
P
|
β
|
P
|
|---|
|
Age
|
0.01
|
0.017
|
0.00
|
0.284
|
0.00
|
0.084
|
0.00
|
0.035
|
0.00
|
0.595
|
–
|
–
|
0.00
|
0.849
|
–
|
–
|
|
Male sex
|
−0.36
|
0.010
|
−0.19
|
0.134
|
−0.01
|
0.948
|
–
|
–
|
0.24
|
0.182
|
–
|
–
|
0.30
|
0.149
|
–
|
–
|
|
White
|
Ref
|
–
|
–
|
–
|
Ref
|
–
|
–
|
–
|
Ref
|
–
|
Ref
|
–
|
Ref
|
–
|
Ref
|
–
|
|
Black
|
0.25
|
0.105
|
–
|
–
|
−0.06
|
0.547
|
–
|
–
|
−0.52
|
0.013
|
−0.44
|
0.017
|
−0.12
|
0.086
|
−0.16
|
0.010
|
|
Asian
|
−0.39
|
0.113
|
–
|
–
|
−0.15
|
0.354
|
–
|
–
|
0.34
|
0.246
|
−0.15
|
0.571
|
0.07
|
0.495
|
0.06
|
0.506
|
|
Mixed
|
−0.17
|
0.675
|
–
|
–
|
−0.04
|
0.888
|
–
|
–
|
0.47
|
0.329
|
0.21
|
0.610
|
0.24
|
0.139
|
0.16
|
0.268
|
|
Other
|
0.16
|
0.571
|
–
|
–
|
0.17
|
0.357
|
–
|
–
|
−0.61
|
0.100
|
−0.52
|
0.095
|
−0.08
|
0.523
|
−0.13
|
0.207
|
|
Disease duration
|
0.01
|
0.037
|
0.01
|
0.208
|
0.01
|
0.197
|
–
|
–
|
0.00
|
0.941
|
–
|
–
|
0.00
|
0.854
|
–
|
–
|
|
RF positive
|
−0.45
|
< 0.001
|
−0.19
|
0.051
|
−0.06
|
0.486
|
–
|
–
|
0.07
|
0.708
|
–
|
–
|
−0.10
|
0.102
|
–
|
–
|
|
Corticosteroids
|
−0.02
|
0.906
|
–
|
–
|
0.05
|
0.685
|
–
|
–
|
0.23
|
0.365
|
–
|
–
|
0.30
|
0.710
|
–
|
–
|
|
DAS28-ESR
|
0.21
|
0.048
|
−0.01
|
0.881
|
−0.08
|
0.254
|
–
|
–
|
−0.05
|
0.708
|
–
|
–
|
0.05
|
0.282
|
–
|
–
|
|
Swollen joint count
|
−0.06
|
0.002
|
−0.02
|
0.227
|
−0.01
|
0.415
|
–
|
–
|
0.08
|
0.006
|
0.04
|
0.184
|
0.00
|
0.664
|
–
|
–
|
|
Tender joint count
|
0.01
|
0.637
|
–
|
–
|
0.00
|
0.926
|
–
|
–
|
0.00
|
0.853
|
–
|
–
|
0.00
|
0.576
|
–
|
–
|
|
PtGA
|
0.01
|
< 0.001
|
0.00
|
0.225
|
0.00
|
0.008
|
0.00
|
0.643
|
−0.01
|
< 0.001
|
0.00
|
0.502
|
0.00
|
0.069
|
0.00
|
0.197
|
|
ESR
|
0.00
|
0.626
|
–
|
–
|
0.00
|
0.971
|
–
|
–
|
0.00
|
0.678
|
–
|
–
|
0.00
|
0.662
|
–
|
–
|
|
DMARD monotherapy
|
Ref
|
–
|
–
|
–
|
Ref
|
–
|
–
|
–
|
Ref
|
–
|
Ref
|
–
|
Ref
|
–
|
–
|
–
|
|
DMARD combination
|
0.05
|
0.646
|
–
|
–
|
0.07
|
0.340
|
–
|
–
|
−0.40
|
0.008
|
−0.44
|
0.002
|
−0.08
|
0.138
|
–
|
–
|
|
No DMARDs
|
−0.65
|
0.171
|
–
|
–
|
−0.10
|
0.738
|
–
|
–
|
−0.01
|
0.989
|
−0.48
|
0.300
|
−0.26
|
0.160
|
–
|
–
|
|
HAQ-DI
|
0.79
|
< 0.001
|
0.67
|
< 0.001
|
−0.21
|
< 0.001
|
−0.21
|
< 0.001
|
−0.65
|
< 0.001
|
−0.57
|
< 0.001
|
0.01
|
0.739
|
–
|
–
|
|
EQ-5D-3L index
|
−1.30
|
< 0.001
|
−0.45
|
0.119
|
0.00
|
0.977
|
–
|
–
|
1.52
|
< 0.001
|
0.27
|
0.527
|
−0.54
|
< 0.001
|
−0.73
|
< 0.001
|
|
EQ-5D-3L pain
|
0.47
|
< 0.001
|
−0.17
|
0.272
|
−0.09
|
0.347
|
–
|
–
|
−0.76
|
< 0.001
|
−0.11
|
0.623
|
0.20
|
< 0.001
|
−0.05
|
0.497
|
|
EQ-5D-3L anxiety/depression
|
0.34
|
< 0.001
|
0.11
|
0.242
|
0.003
|
0.621
|
–
|
–
|
−0.56
|
< 0.001
|
−0.56
|
0.089
|
0.10
|
0.008
|
−0.04
|
0.353
|
- β- and P-values are from linear regression models that included endpoint HAQ-DI score, endpoint EQ-5D-3L index score (rank-transformed), 12-month change in HAQ-DI score or 12-month change in EQ-5D-3L index score as the response variable and each baseline variable as the explanatory variable (univariate model) or all baseline variables with P-values < 0.1 from univariate analysis (multivariate model); P-values shown in bold are significant (< 0.05)
- Abbreviations: DAS28-ESR Disease Activity Score for 28-joint count based on erythrocyte sedimentation rate, DMARD disease-modifying anti-rheumatic drug, EQ-5D-3L 3-level EuroQol 5-Dimensions questionnaire, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, PtGA Patient Global Assessment of Disease Activity on a 10 cm visual analogue scale, Ref reference group, RF rheumatoid factor
